Presentation is loading. Please wait.

Presentation is loading. Please wait.

P3.07-004 Nivolumab for Non-Small Cell Lung Cancer (NSCLC): An Economic Model for Risk Sharing Based on Real-Life Data  Elizabeth Dudnik, Daniel Goldstein,

Published byLorenzo Castillo Modified over 5 years ago

Similar presentations

Presentation on theme: "P3.07-004 Nivolumab for Non-Small Cell Lung Cancer (NSCLC): An Economic Model for Risk Sharing Based on Real-Life Data  Elizabeth Dudnik, Daniel Goldstein,"— Presentation transcript:

1 P Nivolumab for Non-Small Cell Lung Cancer (NSCLC): An Economic Model for Risk Sharing Based on Real-Life Data  Elizabeth Dudnik, Daniel Goldstein, Laila Roisman, Ariel Hammerman, Sari Greenberg-Dotan, Jair Bar, Mor Moskovitz, Sameh Daher, Sivan Shamai, Ekaterina Hanovich, Yelena Shechtman, Mahmoud Abu-Amna, Alona Zer, Mira Wollner, Ofer Merimsky, Arnold Cyjon, Nir Peled  Journal of Thoracic Oncology  Volume 12, Issue 1, Pages S1432-S1433 (January 2017) DOI: /j.jtho Copyright © Terms and Conditions

2 Journal of Thoracic Oncology 2017 12, S1432-S1433DOI: (10.1016/j.jtho.2016.11.2195)
Copyright © Terms and Conditions

Download ppt "P3.07-004 Nivolumab for Non-Small Cell Lung Cancer (NSCLC): An Economic Model for Risk Sharing Based on Real-Life Data  Elizabeth Dudnik, Daniel Goldstein,"

Similar presentations

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Detection of Lung Cancer and EGFR Mutation by Electronic Nose System

Detection of Lung Cancer and EGFR Mutation by Electronic Nose System
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis  Shaohua Lu, Takashi.

MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis  Shaohua Lu, Takashi.
NA  Journal of Thoracic Oncology 

NA  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC)  Edward Garon, Martin Reck, Delvys.

P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC)  Edward Garon, Martin Reck, Delvys.
P1.08-020 The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)  Nicholas Faris, Meredith.

P The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)  Nicholas Faris, Meredith.
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
P1.08-022 Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables  Timothy Edwards, Charlene.

P Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables  Timothy Edwards, Charlene.
Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review  Arianna Casagrande, MD, Federica Pederiva,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review  Arianna Casagrande, MD, Federica Pederiva,
Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 
P2.01-007 Molecular Characterization of Non-Small Cell Lung Cancers (NSCLC) in Young Patients from an Argentine Population  V. Denninghoff, G. Recondo,

P Molecular Characterization of Non-Small Cell Lung Cancers (NSCLC) in Young Patients from an Argentine Population  V. Denninghoff, G. Recondo,
P3.06-003 SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomized Phase III Trial  Yenting Ngai,

P SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomized Phase III Trial  Yenting Ngai,

Similar presentations

Ads by Google